Soleno Therapeutics prices $138M public offering of 3M shares at $46/share

SOLENO THERAPEUTICS INC

Public offering of 3,000,000 shares at $46.00 per share for gross proceeds of ~$138M.
Net proceeds estimated at ~$129.3M after underwriting discounts and expenses.
Underwriters granted 30-day option to purchase up to 450,000 additional shares.
Proceeds to fund R&D for DCCR (Prader-Willi Syndrome) and general corporate purposes.
Offering expected to close on or about May 7, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.